iBio Reveals Pricing for $50 Million Public Offering

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 19 2025

0mins

Source: Globenewswire

Public Offering Announcement: iBio, Inc. has priced an underwritten public offering of pre-funded warrants and Series G and H warrants to purchase shares of its common stock, aiming to raise approximately $50 million.
Warrant Details: The pre-funded warrants are immediately exercisable, while the Series G and H warrants have specific exercise prices and expiration conditions related to clinical trial milestones.
Use of Proceeds: iBio plans to use the proceeds from this offering to advance its preclinical cardiometabolic programs and other pipeline assets, as well as for general corporate purposes.
Forward-Looking Statements: The announcement includes forward-looking statements regarding iBio's future developments and potential risks that could affect the company's performance and offerings.

About the author

Preview

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.